Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
$1.43
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.43
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.52 - $1.90
Previous CloseN/A
Volume1.89M
Average Volume (3M)5.85M
Market Cap
$437.25M
Enterprise ValueN/A
Total Cash (Recent Filing)$32.56M
Total Debt (Recent Filing)$32.96M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding312,320,100
10 Day Avg. Volume2,987,049
30 Day Avg. Volume5,853,609
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)7.36
Price to Sales (P/S)53.80
P/FCF Ratio-4.79
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$9.00Price Target Upside529.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOcugen reported higher-than-expected revenues of $1.8M, compared to consensus estimates of $0.6M, reflecting better financial performance.
Market PotentialOCU410 in Geographic atrophy (GA) represents the largest addressable market for Ocugen, with ~1M patients in the US, and full data from the P2 is expected to be a key catalyst.
Pivotal Study ProgressThe pivotal study for OCU400 in RP is nearing complete enrollment, with data expected in 4Q26, which should enable a rapid turnaround of pivotal data to FDA for completion.
Bears Say
Net Loss IncreaseOcugen reported 3Q25 results with a net loss of ($20.1M), wider than the ($14.7M) in 2Q25, which is due to ramping up of the GARDian study and enrolling the liMeliGhT study in retinitis pigmentosa (RP).
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $1.90 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $437.25M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Mar 27, 2026 which is in 93 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Nov 05, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.014.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 312,320,100 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (529.37% Upside)
$9.00 (529.37% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.42%
12-Months-Change
Fundamentals
Return on Equity
-289.93%
Trailing 12-Months
Asset Growth
32.19%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biotechnology company focused on developing innovative therapies to treat and prevent eye diseases. Primarily operating in the biopharmaceutical sector, Ocugen's core products include its lead candidate, OCU300, an innovative gene therapy for retinal diseases, and a partnership with Bharat Biotech to develop and commercialize COVAXIN, a COVID-19 vaccine, for the U.S. market. The company aims to leverage its expertise in gene therapies and vaccines to address unmet medical needs in ophthalmology and infectious diseases.
OCGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in gene therapy programs and strategic partnerships, alongside promising clinical data. However, the company faced increased operating expenses and a decline in cash position. Overall, the positive advancements and strategic positioning contribute to an optimistic outlook.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$9.00
▲(529.37% Upside)
Technical Analysis
Ownership Overview
1.67% Insiders
5.35% Mutual Funds
2.28% Other Institutional Investors
86.15% Public Companies and Individual Investors